PAVM

PAVmed (PAVM)

PAVmed Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:PAVM

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/09/24	21 : 01	PR Newswire (US)	American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test	NASDAQ:PAVM	PAVmed Inc
2024/09/17	05 : 30	PR Newswire (US)	PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements	NASDAQ:PAVM	PAVmed Inc
2024/09/10	20 : 56	PR Newswire (US)	Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress	NASDAQ:PAVM	PAVmed Inc
2024/09/03	20 : 51	PR Newswire (US)	Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health	NASDAQ:PAVM	PAVmed Inc
2024/08/20	21 : 16	PR Newswire (US)	Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer	NASDAQ:PAVM	PAVmed Inc
2024/08/13	21 : 18	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PAVM	PAVmed Inc
2024/08/13	21 : 16	PR Newswire (US)	The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer	NASDAQ:PAVM	PAVmed Inc
2024/08/13	21 : 01	PR Newswire (US)	PAVmed Provides Business Update and Second Quarter 2024 Financial Results	NASDAQ:PAVM	PAVmed Inc
2024/08/13	05 : 08	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PAVM	PAVmed Inc
2024/08/12	21 : 07	PR Newswire (US)	Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results	NASDAQ:PAVM	PAVmed Inc
2024/08/08	21 : 31	PR Newswire (US)	Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event	NASDAQ:PAVM	PAVmed Inc
2024/08/06	21 : 15	PR Newswire (US)	Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing	NASDAQ:PAVM	PAVmed Inc
2024/08/05	21 : 15	PR Newswire (US)	Lucid Diagnostics to Participate in Upcoming Investor Conferences	NASDAQ:PAVM	PAVmed Inc
2024/07/30	21 : 15	PR Newswire (US)	PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024	NASDAQ:PAVM	PAVmed Inc
2024/07/29	21 : 15	PR Newswire (US)	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024	NASDAQ:PAVM	PAVmed Inc
2024/07/23	21 : 01	PR Newswire (US)	Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume	NASDAQ:PAVM	PAVmed Inc
2024/07/11	21 : 31	PR Newswire (US)	Lucid Diagnostics Launches New Corporate Website	NASDAQ:PAVM	PAVmed Inc
2024/07/02	20 : 55	PR Newswire (US)	Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population	NASDAQ:PAVM	PAVmed Inc
2024/06/13	20 : 58	PR Newswire (US)	PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	NASDAQ:PAVM	PAVmed Inc
2024/06/12	21 : 05	PR Newswire (US)	4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing	NASDAQ:PAVM	PAVmed Inc
2024/05/14	09 : 43	PR Newswire (US)	PAVmed Provides Business Update and First Quarter 2024 Financial Results	NASDAQ:PAVM	PAVmed Inc
2024/05/13	21 : 00	PR Newswire (US)	Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results	NASDAQ:PAVM	PAVmed Inc
2024/05/09	20 : 49	PR Newswire (US)	Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall	NASDAQ:PAVM	PAVmed Inc
2024/05/07	20 : 39	PR Newswire (US)	Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors	NASDAQ:PAVM	PAVmed Inc
2024/05/03	21 : 35	PR Newswire (US)	PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024	NASDAQ:PAVM	PAVmed Inc
2024/05/02	21 : 35	PR Newswire (US)	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024	NASDAQ:PAVM	PAVmed Inc
2024/05/02	20 : 49	PR Newswire (US)	Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing	NASDAQ:PAVM	PAVmed Inc
2024/04/30	20 : 35	PR Newswire (US)	PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	NASDAQ:PAVM	PAVmed Inc
2024/04/29	21 : 47	PR Newswire (US)	Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month	NASDAQ:PAVM	PAVmed Inc
2024/04/08	21 : 30	PR Newswire (US)	Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:PAVM	PAVmed Inc